TB Alliance and Lupin partner to manufacture anti-TB drug pretomanid

The TB Alliance has granted Lupin a non-exclusive license to manufacture the anti-TB drug pretomanid as part of the three-drug “BPaL” regimen. Lupin intends to commercialise the anti-tuberculosis (TB) medicine in approximately 140 countries and territories, including many of the highest TB-burden countries around the world, the pharma major said in a statement.

Speaking in this regard, Mel Spigelman, President and CEO, TB Alliance, said, “TB Alliance is committed to ensure its products are widely available and affordable to those who need them. Partnering with Lupin, a well-established manufacturer with experience delivering high-quality TB therapies, will help further enable widespread access to our novel regimen while promoting a competitive market to drive affordability.”

Adding to it, Nilesh Gupta, Managing Director, Lupin, added, “As a global leader in anti-TB medicines, Lupin is committed to enhancing access to bridge unmet needs in countries where it is needed the most. This collaboration with TB Alliance leverages our strength and expertise to contribute to better global health.”